{"title":"生物仿制药障碍清除似乎是为特朗普/民主党协议量身定制的:新生物仿制药的开发和少数获批药物的营销受阻。","authors":"Stephen Barlas","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The United States is lagging behind Europe in biosimilar use, and missing out on a wider range of medication options and huge savings in drug expenditures. What's causing the holdup?</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 2","pages":"45-68"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355054/pdf/ptj4402045.pdf","citationCount":"0","resultStr":"{\"title\":\"Biosimilar Roadblock Removals Seem Tailor-Made for Trump/Democrats Agreement: Development of New Biosimilar Drugs and Marketing of Few Approved Drugs Stymied.\",\"authors\":\"Stephen Barlas\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The United States is lagging behind Europe in biosimilar use, and missing out on a wider range of medication options and huge savings in drug expenditures. What's causing the holdup?</p>\",\"PeriodicalId\":38773,\"journal\":{\"name\":\"P and T\",\"volume\":\"44 2\",\"pages\":\"45-68\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355054/pdf/ptj4402045.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"P and T\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"P and T","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Biosimilar Roadblock Removals Seem Tailor-Made for Trump/Democrats Agreement: Development of New Biosimilar Drugs and Marketing of Few Approved Drugs Stymied.
The United States is lagging behind Europe in biosimilar use, and missing out on a wider range of medication options and huge savings in drug expenditures. What's causing the holdup?
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
